Cited by

• The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection.

  Jin Q, Chen H, Wang X, Zhao L, Xu Q, Wang H, Li G, Yang X, Ma H, Wu H, Ji X. Jin Q, et al. PLoS One. 2015 Jul 8;10(7):e0131894. doi: 10.1371/journal.pone.0131894. eCollection 2015. PLoS One. 2015. PMID: 26154172 Free PMC article.
• Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.

  Dawson JRD, Wadman GM, Zhang P, Tebben A, Carter PH, Gu S, Shroka T, Borrega-Roman L, Salanga CL, Handel TM, Kufareva I. Dawson JRD, et al. bioRxiv [Preprint]. 2024 Feb 12:2023.11.15.567150. doi: 10.1101/2023.11.15.567150. bioRxiv. 2024. PMID: 38014122 Free PMC article. Preprint.
• Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5.

  Berg C, Spiess K, Lüttichau HR, Rosenkilde MM. Berg C, et al. Pharmacol Res Perspect. 2016 Oct 18;4(6):e00262. doi: 10.1002/prp2.262. eCollection 2016 Dec. Pharmacol Res Perspect. 2016. PMID: 28097000 Free PMC article.
• Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

  Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR. Heredia A, et al. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20476-81. doi: 10.1073/pnas.0810843106. Epub 2008 Dec 15. Proc Natl Acad Sci U S A. 2008. PMID: 19075241 Free PMC article.
• Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.

  Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J, Zhang W, Xie X, Yang H, Jiang H, Cherezov V, Liu H, Stevens RC, Zhao Q, Wu B. Tan Q, et al. Science. 2013 Sep 20;341(6152):1387-90. doi: 10.1126/science.1241475. Epub 2013 Sep 12. Science. 2013. PMID: 24030490 Free PMC article.